CTNNB1 Syndrome Study Explores Beta-Catenin Defects

Key Takeaways

• Researchers in Spain are investigating the molecular basis of CTNNB1 Syndrome, a rare genetic disorder linked to beta-catenin mutations.
• The project integrates biophysics, AI-driven protein modeling, and brain organoids to study disrupted brain development.
• Findings may inform future targeted therapies, offering long-term clinical relevance for rare disease research.

Understanding a Rare but Impactful Neurodevelopmental Disorder: CTNNB1 Syndrome

On Rare Disease Day, researchers from the Biofisika Institute highlighted progress in a national project focused on CTNNB1 neurodevelopmental syndrome, a rare condition caused by pathogenic variants in the beta-catenin protein. Although fewer than 50 patients have been identified in Spain, rare diseases collectively affect nearly three million individuals nationwide, underscoring the broader public health relevance.

The study is led by Sonia Bañuelos, who also teaches biochemistry and molecular biology at the University of the Basque Country. Her team aims to clarify how CTNNB1 mutations interfere with normal brain formation at the molecular level.

Beta-Catenin’s Role in Brain Development

Beta-catenin is a multifunctional protein essential for cell adhesion and synaptic plasticity, processes critical during embryonic brain development and ongoing neural function. In CTNNB1 syndrome, most genetic variants result in truncated or misfolded proteins, impairing their interaction with cadherins and destabilizing neural tissue architecture.

To address this, the Biofisika Institute collaborates with neuropsychology specialists from the University of Deusto, molecular geneticists at the Biobizkaia Institute, and the brain organoid platform at the Achucarro Neuroscience Center. The Spanish Association of CTNNB1 Syndrome Patients also plays an active role, ensuring patient-centered research priorities.

AI, Biophysics, and Organoids in CTNNB1 Syndrome Research

Using AI-supported structural protein analysis, researchers predict how specific CTNNB1 mutations alter beta-catenin–cadherin binding. These predictions are experimentally validated through biophysical assays using mutant proteins produced in bacterial systems.

To bridge molecular findings with neurodevelopmental outcomes, brain organoids are employed to model how these defects influence nervous tissue formation. While the work is foundational, it may guide rational therapy design in the future.

Why This Research Matters for HCPs

For clinicians and researchers, this study reinforces the importance of mechanism-driven rare disease research. As Dr. Bañuelos notes, understanding disease biology is a prerequisite for any therapeutic strategy, especially in genetically complex neurodevelopmental disorders.

Stay informed on upcoming neurology CME conferences and clinical updates. Upgrade your skills at the American Neurology Summit 2026.

Source:

University of the Basque Country